News
Press ReleaseRevive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Revive Therapeutics Advances Inflammatory Liver Disorders Programs for Autoimmune Hepatitis and Liver Transplantation
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.
Revive Therapeutics Provides Update on Phase 3 Clinical Trial for Bucillamine in COVID-19
The biosynthetic platform developed by Dr. Gavin Williams provides a potential simple and efficient method for rapidly producing natural products, such as psilocybin, using an engineered enzymatic pathway in E. coli.